Spotlight on Dermatology
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus
StartActivity Details
1.0 ABIM MOC Part II Points
Expires: April 9, 2022
Accredited By
Target Audience
The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.
Learning Objectives
As a result of participation in this activity, participants should increase their ability to:
- Utilize a treat-to-target approach to individualize treatment in patients with SLE.
- Improve assessment of SLE disease activity and achievement of treatment goals.
- Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.
Activity Description
In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.
Faculty
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
- Presenters: Maria Dall’Era, MD, Aileen Olivares
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Presenter: Sheetal Desai, MD, MSEd
-
- Advisory Board: Janssen, GlaxoSmithKline
- Speakers Bureau: Janssen, GlaxoSmithKline
CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Activity Details
1.0 ABIM MOC Part II Points
Expires: April 9, 2022
Accredited By
Target Audience
The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.
Learning Objectives
As a result of participation in this activity, participants should increase their ability to:
- Utilize a treat-to-target approach to individualize treatment in patients with SLE.
- Improve assessment of SLE disease activity and achievement of treatment goals.
- Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.
Activity Description
In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.
Faculty
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
- Presenters: Maria Dall’Era, MD, Aileen Olivares
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Presenter: Sheetal Desai, MD, MSEd
-
- Advisory Board: Janssen, GlaxoSmithKline
- Speakers Bureau: Janssen, GlaxoSmithKline
CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Dermatology Presentations
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care
StartActivity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Activity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus
StartActivity Details
1.0 ABIM MOC Part II Points
Expires: April 9, 2022
Accredited By
Target Audience
The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.
Learning Objectives
As a result of participation in this activity, participants should increase their ability to:
- Utilize a treat-to-target approach to individualize treatment in patients with SLE.
- Improve assessment of SLE disease activity and achievement of treatment goals.
- Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.
Activity Description
In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.
Faculty
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
- Presenters: Maria Dall’Era, MD, Aileen Olivares
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Presenter: Sheetal Desai, MD, MSEd
-
- Advisory Board: Janssen, GlaxoSmithKline
- Speakers Bureau: Janssen, GlaxoSmithKline
CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Activity Details
1.0 ABIM MOC Part II Points
Expires: April 9, 2022
Accredited By
Target Audience
The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.
Learning Objectives
As a result of participation in this activity, participants should increase their ability to:
- Utilize a treat-to-target approach to individualize treatment in patients with SLE.
- Improve assessment of SLE disease activity and achievement of treatment goals.
- Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.
Activity Description
In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.
Faculty
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
- Presenters: Maria Dall’Era, MD, Aileen Olivares
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Presenter: Sheetal Desai, MD, MSEd
-
- Advisory Board: Janssen, GlaxoSmithKline
- Speakers Bureau: Janssen, GlaxoSmithKline
CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Basal Cell Carcinoma: To Targeted Therapy and Beyond—Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape
StartActivity Details
ABIM MOC Points
Expires: April 8, 2022
Jointly Provided By
Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
- Evaluate the role and place of immunotherapy in managing patients with advanced BCC
Activity Description
Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.
Statement of Educational Need
Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.
Chair
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna
Faculty
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY
Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 medical knowledge MOC points in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.
Activity Details
ABIM MOC Points
Expires: April 8, 2022
Jointly Provided By
Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
- Evaluate the role and place of immunotherapy in managing patients with advanced BCC
Activity Description
Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.
Statement of Educational Need
Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.
Chair
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna
Faculty
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY
Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 medical knowledge MOC points in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.
Recent Advances in the Management of Psoriasis
StartActivity Details
AANP Contact Hours
AAPA Category 1 CME credit
Expires: December 30, 2021
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the pathophysiology and comorbidities associated with psoriasis.
- Apply current guideline-directed recommendations to the management of patients with psoriasis.
- Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
- Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.
Activity Description
Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.
Activity Co-Chairs
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI
Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
1.0 contact hour(s) of continuing education (which includes 0.67 hours
of pharmacology) by the American Association of Nurse Practitioners. Activity
ID 20124656. This activity was planned in accordance with AANP Accreditation
Standards and Policies.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 1 AAPA Category 1 CME credits.
Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit
commensurate with the extent of their participation. AAPA reference number:
CME-201757.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.
MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an
Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the
Merit-based Incentive Payment Program (MIPS). Participants who successfully
complete the activity and its performance assessment will receive printable
documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
AANP Contact Hours
AAPA Category 1 CME credit
Expires: December 30, 2021
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Review the pathophysiology and comorbidities associated with psoriasis.
- Apply current guideline-directed recommendations to the management of patients with psoriasis.
- Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
- Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.
Activity Description
Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.
Activity Co-Chairs
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI
Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for
1.0 contact hour(s) of continuing education (which includes 0.67 hours
of pharmacology) by the American Association of Nurse Practitioners. Activity
ID 20124656. This activity was planned in accordance with AANP Accreditation
Standards and Policies.
This activity has been
reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.
This activity is designated for 1 AAPA Category 1 CME credits.
Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit
commensurate with the extent of their participation. AAPA reference number:
CME-201757.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.
MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an
Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the
Merit-based Incentive Payment Program (MIPS). Participants who successfully
complete the activity and its performance assessment will receive printable
documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There
StartActivity Details
Expires: December 7, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
- Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
- Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
- Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
- Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.
Activity Description
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.
Agenda
Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO
Immunopathogenesis of SLE: Implications for Disease Manifestations
and Treatment
Daniel J. Wallace, MD, FACP, MACR
Advances in the Treatment of SLE
Richard A. Furie, MD
Clinical Cases
Moderated by Leonard H. Calabrese, DO
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY
Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA
Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: December 7, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
- Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
- Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
- Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
- Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.
Activity Description
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.
Agenda
Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO
Immunopathogenesis of SLE: Implications for Disease Manifestations
and Treatment
Daniel J. Wallace, MD, FACP, MACR
Advances in the Treatment of SLE
Richard A. Furie, MD
Clinical Cases
Moderated by Leonard H. Calabrese, DO
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY
Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA
Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Chronic Idiopathic Urticaria Curbside Consults ̶ Impact of Guidelines on Patient Outcomes in Chronic Idiopathic Urticaria: A Closer Look
StartActivity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Lang compare existing guidelines for treating urticaria, providing guidance on the application of guidelines recommendations to optimize diagnosis and management of CIU/CSU.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Lang compare existing guidelines for treating urticaria, providing guidance on the application of guidelines recommendations to optimize diagnosis and management of CIU/CSU.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Chronic Idiopathic Urticaria Curbside Consults ̶ Re-thinking the Burden of Chronic Idiopathic Urticaria: Assessing the Quality of Life
StartActivity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work, and activity.
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Khan discuss the burden of CIU/CSU and its impact on patient quality of life (QoL), including disease-specific measures for assessing QoL and strategies for selecting the best treatment to minimize disease burden.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine and Pediatrics
Allergy & Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosure:
Consulting Fee: Aimmune
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work, and activity.
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Khan discuss the burden of CIU/CSU and its impact on patient quality of life (QoL), including disease-specific measures for assessing QoL and strategies for selecting the best treatment to minimize disease burden.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine and Pediatrics
Allergy & Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosure:
Consulting Fee: Aimmune
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com